In this setting, two robust clinical trials (FeDeriCa and PHranceSCa studies) demonstrated the efficacy, safety and preferences of pertuzumab and trastuzumab fixed-dose combination for subcutaneous injection (PH FDC SC) for the treatment of HER2-positive BC. This evidence concerns the gene ERBB2 and breast cancer.